S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 29, 2004

Primary Completion Date

November 30, 2010

Study Completion Date

January 8, 2015

Conditions
Lymphoma
Interventions
BIOLOGICAL

rituximab

250 mg/m\^2, as part of Zevalin regimen

DRUG

Cyclophosphamide

750 mg/m\^2

DRUG

doxorubicin hydrochloride

50 mg/m\^2

DRUG

prednisone

100 mg

DRUG

vincristine sulfate

1.4 mg/m\^2

RADIATION

radiation therapy

4000-5000 cGy total

BIOLOGICAL

Yttrium-90 ibritumomab tiuxetan

0.4 mCi/kg

BIOLOGICAL

Indium-111 ibritumomab tiuxetan

5 mCi

Trial Locations (48)

14642

James P. Wilmot Cancer Center at University of Rochester Medical Center, Rochester

29615

CCOP - Greenville, Greenville

44131

Community Oncology Group at Cleveland Clinic Cancer Center, Independence

44195

Cleveland Clinic Taussig Cancer Center, Cleveland

44307

McDowell Cancer Center at Akron General Medical Center, Akron

44691

Cleveland Clinic - Wooster, Wooster

45267

Charles M. Barrett Cancer Center at University Hospital, Cincinnati

48075

Providence Cancer Institute at Providence Hospital - Southfield Campus, Southfield

49017

Battle Creek Health System Cancer Care Center, Battle Creek

49307

Mecosta County Medical Center, Big Rapids

49442

Hackley Hospital, Muskegon

49503

Butterworth Hospital at Spectrum Health, Grand Rapids

CCOP - Grand Rapids, Grand Rapids

Lacks Cancer Center at Saint Mary's Health Care, Grand Rapids

49519

Metro Health Hospital, Wyoming

49684

Munson Medical Center, Traverse City

60153

Cardinal Bernardin Cancer Center at Loyola University Medical Center, Maywood

60540

Edward Hospital Cancer Center, Naperville

62526

Decatur Memorial Hospital Cancer Care Institute, Decatur

66606

Cotton-O'Neil Cancer Center, Topeka

66720

Cancer Center of Kansas, PA - Chanute, Chanute

67042

Cancer Center of Kansas, PA - El Dorado, El Dorado

Cancer Center of Kansas, PA - Salina, Salina

67068

Cancer Center of Kansas, PA - Kingman, Kingman

67114

Cancer Center of Kansas, PA - Newton, Newton

67124

Cancer Center of Kansas, PA - Pratt, Pratt

67152

Cancer Center of Kansas, PA - Wellington, Wellington

67156

Cancer Center of Kansas, PA - Winfield, Winfield

67208

Associates in Womens Health, PA - North Review, Wichita

Cancer Center of Kansas, PA - Medical Arts Tower, Wichita

67214

Cancer Center of Kansas, PA - Wichita, Wichita

CCOP - Wichita, Wichita

Via Christi Cancer Center at Via Christi Regional Medical Center, Wichita

Wesley Medical Center, Wichita

67301

Cancer Center of Kansas-Independence, Independence

67357

Cancer Center of Kansas, PA - Parsons, Parsons

67801

Cancer Center of Kansas, PA - Dodge City, Dodge City

67901

Southwest Medical Center, Liberal

83712

Mountain States Tumor Institute at St. Luke's Regional Medical Center, Boise

91505

Providence Saint Joseph Medical Center - Burbank, Burbank

98104

Minor and James Medical, PLLC, Seattle

98112

Group Health Central Hospital, Seattle

98122

Polyclinic First Hill, Seattle

99508

Alaska Regional Hospital Cancer Center, Anchorage

Providence Cancer Center, Anchorage

62781-0001

Regional Cancer Center at Memorial Medical Center, Springfield

98122-4307

Swedish Cancer Institute at Swedish Medical Center - First Hill Campus, Seattle

98195-6043

University Cancer Center at University of Washington Medical Center, Seattle

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

SWOG Cancer Research Network

NETWORK

NCT00070018 - S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter